Circulating soluble CD30 levels in primary Sjögren's syndrome, SLE and rheumatoid arthritis.
Ichikawa
Y
Y
Yoshida
M
M
Yamada
C
C
Horiki
T
T
Hoshina
Y
Y
Uchiyama
M
M
D000974:Antibodies, Antinuclear / Q000032:analysis; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy; D001324:Autoantigens / Q000032:analysis; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D017730:Ki-1 Antigen / Q000097:blood*; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000188:drug therapy; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D020733:RNA, Small Cytoplasmic; D012261:Ribonucleoproteins / Q000032:analysis; D012859:Sjogren's Syndrome / Q000097:blood* / Q000188:drug therapy; D000099207:SS-A Antigen
D000974:Antibodies, Antinuclear; D018501:Antirheumatic Agents; D001324:Autoantigens; D007074:Immunoglobulin G; D017730:Ki-1 Antigen; D011239:Prednisolone; D020733:RNA, Small Cytoplasmic; D012261:Ribonucleoproteins; D000099207:SS-A Antigen; C116006:RO60 protein, human